BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+0.68%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.2B
AUM Growth
+$10.2B
(-7.4%)
Cap. Flow
-$627M
Cap. Flow
% of AUM
-6.14%
Top 10 Holdings %
Top 10 Hldgs %
83.92%
Holding
141
New
7
Increased
13
Reduced
18
Closed
7
Top Buys
Top Sells
| 1 |
AbbVie
ABBV
|
$793M |
| 2 |
Exelixis
EXEL
|
$28.7M |
| 3 |
TG Therapeutics
TGTX
|
$15.5M |
| 4 |
Arrowhead Research
ARWR
|
$13.6M |
| 5 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
$13.3M |
Sector Composition
| 1 | Healthcare | 81.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ECYT
126
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
-868,983
| Closed | -$2.69M |
|
|
ISEE
127
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-35,649
| Closed | -$1.64M |
|
|
128
TG Therapeutics
TGTX
$5.03B
| – | – |
-2,003,991
| Closed | -$15.5M |
|
129
Savara
SVRA
$591M
| – | – |
-8,584,051
| Closed | -$944K |
|
|
130
Arrowhead Research
ARWR
$3.84B
| – | – |
-1,856,967
| Closed | -$13.6M |
|